Developing a new execution strategy for the production of zoning parcels according to the parcel plan

Arazi ve Arsa Düzenlemeleri (AAD), planlı şehircilik ilkeleri kapsamında uygulaması yerel yönetimlerce zorunlu olan uygulamalar kapsamındadır. Bu uygulamayla birçok parselin, parsel maliklerinden izin alınmaksızın İmar Kanunun 18. Maddesi ve uygulama yönetmeliği ile Planlı Alanlar Yönetmeliği hükümlerine ve uygulama imar planına göre parselasyonu yapılarak yapılaşmaya uygun hale getirilmektedir. Günümüz meri mevzuatı kapsamında parselasyon planına göre müstakil yapı yapılmasına müsait tapuya tescilli imar parseli üretimine ilişkin uygulamalar alan esaslı ve kısmen değer esaslı olarak yapılmakta olup her parselde eşit oranda değer artışı olduğu kabul edilmektedir. Ancak; bu durum her zaman her uygulamada sağlanamamaktadır ve bazı parsellerde diğer parsellere göre daha farklı değer artışları yaşandığı için hukuk dilinde haksız zenginleşmeye yol açmaktadır. İmar uygulamaları çalışmalarında alan esaslı çalışma yerine taşınmazın kadastro ve imar parsel değerlerine göre derece dönüşüm esaslı uygulama stratejisi geliştirilmiş, haksız zenginleşmeyi önleyebilecek daha adil bir model oluşturulmuştur. Çalışmada; Erzurum Büyükşehir Belediyesince kesinleştirilip tapu müdürlüğünce tescil edilen gerçek bir imar uygulaması incelenerek, her parselden eşit Düzenleme Ortaklık Payı (DOP) kesintisi uygulamasına alternatif olacak şekilde, kadastro ve imar parsellerinin değerlerinin oranlanmasından derece dönüşüm modeli geliştirilmiş, imar parseli tahsisinde 1163 sayılı Kooparatifler Kanununun 23. Maddesine uygun olarak şerefiye esaslı tahsis modeli uygulanmış ve imar uygulaması nedeniyle oluşan değer artışı malikler arasında paylaştırılarak değer eşitliği sağlanmıştır.Land arrangements (LA) is within the scope of practices that are mandatory by local governments within the scope of planned urbanism principles. With this application; Cadastral parcels are made suitable for construction by subdividing them according to the zoning legislation and implementation zoning plan, without obtaining permission from the parcel owners. Within the scope of today's Turkish legislation; Applications for the production of zoning parcels, which are suitable for detached structures according to the parceling plan and registered with the title deed, are made on an area-based basis and it is accepted that there is an equal increase in value in each parcel. However; Equal increase in value cannot be achieved in every application and since some parcels experience different value increases compared to other parcels, it leads to unjust enrichment in the language of law. In the zoning implementation studies, an application strategy based on degree conversion has been developed according to the cadastral and zoning parcel values of the real estate instead of the area-based work. Thus, a fairer model has been created that can prevent unjust enrichment. In the study, a real zoning application, which was finalized by the Erzurum Metropolitan Municipality and registered by the land registry directorate, was examined. In practice; As an alternative to the application of equal Regulation Partnership Share (RPS) deduction from each parcel, a degree conversion model has been developed from the ratio of the values of the cadastral and zoning parcels. In this study, goodwill-based allocation model has been applied

Baseline aortic pre-ejection interval predicts reverse remodeling and clinical improvement after cardiac resynchronization therapy

Background: Cardiac resynchronization therapy (CRT) has been shown to reduce heart failure-related morbidity and mortality. However, approximately one in three patients do not respond to CRT. The aim of the current study was to determine the parameter(s) which predict reverse remodeling and clinical improvement after CRT. Methods: A total of 54 patients (43 male, 11 female; mean age 61.9 ± 10.5 years) with heart failure and New York Heart Association (NYHA) class III–IV symptoms and in whom left ventricular ejection fraction (LVEF) was £ 35% and QRS duration was ≥ 120 ms, despite optimal medical therapy, were enrolled. An echocardiographic examination was performed before, and six months after, CRT. An echocardiographic response was defined as a reduction of end-systolic volume ≥ 10% after six months, and a clinical response was defined as a reduction ≥ 1 in the NYHA functional class score. Results: An echocardiographic response was observed in 38 (70.4%) of the patients and a clinical response occurred in 41 (75.9%) of the patients. Of the dyssynchrony parameters, only the aortic pre-ejection interval (APEI) was observed to significantly predict the clinical response (p = 0.048) and echocardiographic response (p = 0.037). A 180.5 ms cut-off value for the APEI predicted the clinical response with a sensitivity of 92.3% and a specificity of 39%, and the echocardiographic response with a sensitivity of 93.0% and a specificity of 42%. Conclusions: APEI derived from pulsed-wave Doppler, which is available in every echocardiography machine, is a simple and practical method that could be used to select patients for CRT. (Cardiol J 2011; 18, 6: 639–647

Case report of radiation-induced lung injury with trastuzumab emtansine: the lung also matters

With an increase in the number of agents used concurrently with radiotherapy (RT), a new research area has emerged regarding toxicity. Here, we present a case of a 47-year-old woman presenting with radiation-induced lung injury (RILI) that occurred six months after the end of RT with concomitant and sequential use of trastuzumab-emtansine (T-DM1) with RT. The patient’s T-DM1 treatment was discontinued because of RILI. Antibiotic and methylprednisolone treatments were started. The steroid dose was gradually tapered and completely discontinued after full recovery. If new agents are used concurrently with RT, the toxicity profile of new agents should be kept in mind

The impact of hybrid capture-based comprehensive genomic profiling on treatment strategies in patients with solid tumors

Objective: The development of bioinformatics and comprehensive genomic profiling (CGP) has provided insights into the ap-plicability and functionality of the genomic alterations (GA). In this study, we evaluated the impact of CGP on the treatment plan and outcomes in a significant number of patients. Material and Methods: We carried out a retrospective case-control study on 164 adult patients with advanced solid tumors from 15 oncology centers in Türkiye. Results: In all cases, CGP was performed within 23.8 [standard deviation (SD)±32.1] months of initial diagnosis. Non-small cell lung carcinoma, breast cancer, unknown primary carcinoma, colorectal carcinoma, and sarcoma were among the most common tumor types, accounting for 61.5% of all cases. CGP was performed immediately after the diagnosis of advanced cancer in 13 patients (7.9%). In 158 patients (96.4%), at least one GA was found as per the CGP report. Also, in the reports, the average tumor mutational burden (TMB) and GAs were 7.3 (SD±8.7) mut/Mb and 3.5 (SD±2.0), respectively. According to CGP reports, 58 patients had 79 evidence-based drug suggestions for their particular tumor type, whereas 97 patients had 153 evidence-based drug suggestions for another tumor type. After the primary oncologist interpreted the CGP reports, significant changes were made to the treatment of 35 (21.3%) patients. Conclusion: We strongly believe that in the future, high-TMB or other tumor-agnostic biomarkers will become much more afford-able, and CGP will serve as one of the major decision-making tools for the treatment of patients along with pathological, radiological or lab-oratory tests

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412):a randomised, double-blind, phase 3 trial

Background: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC.Methods: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy. Randomisation was done using an interactive response technology system and was stratified by investigator's choice of radiotherapy regimen, tumour site and p16 status, and disease stage, with participants randomly assigned in blocks of four per stratum. Participants, investigators, and sponsor personnel were masked to treatment assignments. Local pharmacists were aware of assignments to support treatment preparation. Pembrolizumab and placebo were administered intravenously once every 3 weeks for up to 17 doses (one before chemoradiotherapy, two during chemoradiotherapy, 14 as maintenance therapy). Chemoradiotherapy included cisplatin (100 mg/m2) administered intravenously once every 3 weeks for two or three doses and accelerated or standard fractionation radiotherapy (70 Gy delivered in 35 fractions). The primary endpoint was event-free survival analysed in all randomly assigned participants. Safety was analysed in all participants who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03040999, and is active but not recruiting.Findings: Between April 19, 2017, and May 2, 2019, 804 participants were randomly assigned to the pembrolizumab group (n=402) or the placebo group (n=402). 660 (82%) of 804 participants were male, 144 (18%) were female, and 622 (77%) were White. Median study follow-up was 47·7 months (IQR 42·1–52·3). Median event-free survival was not reached (95% CI 44·7 months–not reached) in the pembrolizumab group and 46·6 months (27·5–not reached) in the placebo group (hazard ratio 0·83 [95% CI 0·68–1·03]; log-rank p=0·043 [significance threshold, p≤0·024]). 367 (92%) of 398 participants treated in the pembrolizumab group and 352 (88%) of 398 participants treated in the placebo group had grade 3 or worse adverse events. The most common grade 3 or worse adverse events were decreased neutrophil count (108 [27%] of 398 participants in the pembrolizumab group vs 100 [25%] of 398 participants in the placebo group), stomatitis (80 [20%] vs 69 [17%]), anaemia (80 [20%] vs 61 [15%]), dysphagia (76 [19%] vs 62 [16%]), and decreased lymphocyte count (76 [19%] vs 81 [20%]). Serious adverse events occurred in 245 (62%) participants in the pembrolizumab group versus 197 (49%) participants in the placebo group, most commonly pneumonia (43 [11%] vs 25 [6%]), acute kidney injury (33 [8%] vs 30 [8%]), and febrile neutropenia (24 [6%] vs seven [2%]). Treatment-related adverse events led to death in four (1%) participants in the pembrolizumab group (one participant each from aspiration pneumonia, end-stage renal disease, pneumonia, and sclerosing cholangitis) and six (2%) participants in the placebo group (three participants from pharyngeal haemorrhage and one participant each from mouth haemorrhage, post-procedural haemorrhage, and sepsis).Interpretation: Pembrolizumab plus chemoradiotherapy did not significantly improve event-free survival compared with chemoradiotherapy alone in a molecularly unselected, locally advanced HNSCC population. No new safety signals were seen. Locally advanced HNSCC remains a challenging disease that requires better treatment approaches.Funding: Merck Sharp &amp; Dohme, a subsidiary of Merck &amp; Co, Rahway, NJ, USA.</p

Honey Plants of Düzce University Ornamental and Medicinal Plants Botanical Garden

In this study, melliferous plants that the honey bee (Apis mellifera L.) can benefit from among the taxa planted in Düzce University Ornamental and Medicinal Plants Botanical Garden, are presented. Among the 451 taxa planted in the botanical garden, those with these characteristics were determined by reviewing studies on the subject. Of the 165 taxa (36.58%) included in the honey plant class; 119 contain both nectar and pollen, 25 contain pollen, 13 contain nectar, 4 contain both pollen and insect secretion (IS) or sweet sap (SS), 2 contain pollen, nectar and IS or SS, 1 contain both nectar and SS, 1 contain only IS. In order to prevent the decrease in pollinator and pollinator insects, whose numbers are decreasing due to global climate change, a "Bee and Insect Hotel" was placed in the botanical garden. For this reason, the majority of the plants selected for planting were chosen from taxa with honey plant properties. The main purpose here is both to pollinate the plants in the botanical garden and to show and explain the effects of insect species on pollination through nature education

Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

Purpose The interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months). This prespecified analysis provides final overall survival (OS) and safety data. Methods The open-label, single-arm LUCY trial of olaparib (300 mg, twice daily) enrolled adults with gBRCAm or somatic BRCA-mutated (sBRCAm), HER2-negative mBC. Patients had previously received a taxane or anthracycline for neoadjuvant/adjuvant or metastatic disease and up to two lines of chemotherapy for mBC. Results Of 563 patients screened, 256 (gBRCAm, n  = 253; sBRCAm, n  = 3) were enrolled. In the gBRCAm cohort, median investigator-assessed PFS (primary endpoint) was 8.18 months and median OS was 24.94 months. Olaparib was clinically effective in all prespecified subgroups: hormone receptor status, previous chemotherapy for mBC, previous platinum-based chemotherapy (including by line of therapy), and previous cyclin-dependent kinase 4/6 inhibitor use. The most frequent treatment-emergent adverse events (TEAEs) were nausea (55.3%) and anemia (39.2%). Few patients (6.3%) discontinued olaparib owing to a TEAE. No deaths associated with AEs occurred during the study treatment or 30-day follow-up. Conclusion The LUCY patient population reflects a real-world population in line with the licensed indication of olaparib in mBC. These findings support the clinical effectiveness and safety of olaparib in patients with gBRCAm, HER2-negative mBC. Clinical trial registration Clinical trials registration number: NCT03286842AstraZenecahttp://dx.doi.org/10.13039/100004325Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, US

CFD MODELLING OF INDUSTRIAL AIR CURTAINS WITH HEATING UNIT

Industrial air curtains are used to prevent air from moving from one space to another space or to environment. The most common used type is downward-facing blower fan mounted over the entrance of a building, or an opening door between two spaces conditioned at different temperatures. In many factories and industrial buildings, heating or cooling applications are difficult due to the huge doors. These huge doors cause heat loses with convection phenomena of the inside air. In this study an air curtain having heater unit is analyzed numerically by CFD. The height of the air curtain from the bottom side is vary between 2.5 m, 3 m, 4m, 5m and 6 m mounted over the entrance door of the conditioned volume. For CFD studies proper mesh structure is created on the flow domain and Shear Stress Transport (SST) k-omega models were used in Unsteady Reynolds Averaged Navier-Stokes (URANS) computations. The blowing temperature of the air curtain has adjusted to 60 °C with the inside temperature was aimed to kept at +7°C while the outside temperature was -5°C. It is found that there is less flow occurred to the environment from conditioned volume at 2.5 3, 4 and 5 meter height cases. In these cases, the air curtain also contributes the heating of the conditioned room. But some ratio of the air flows through the atmosphere and the room cannot kept at the +7°C initial temperature at 6 m case. It is also found that the heating ratio at different blowing heights differs between 0,89-1,98 comparing the case without an air curtain.</jats:p

CFD MODELLING OF INDUSTRIAL AIR CURTAINS WITH HEATING UNIT

Industrial air curtains are used to prevent air from moving from one space to another space or to environment. The most common used type is downward-facing blower fan mounted over the entrance of a building, or an opening door between two spaces conditioned at different temperatures. In many factories and industrial buildings, heating or cooling applications are difficult due to the huge doors. These huge doors cause heat loses with convection phenomena of the inside air. In this study an air curtain having heater unit is analyzed numerically by CFD. The height of the air curtain from the bottom side is vary between 2.5 m, 3 m, 4m, 5m and 6 m mounted over the entrance door of the conditioned volume. For CFD studies proper mesh structure is created on the flow domain and Shear Stress Transport (SST) k-omega models were used in Unsteady Reynolds Averaged Navier-Stokes (URANS) computations. The blowing temperature of the air curtain has adjusted to 60 °C with the inside temperature was aimed to kept at +7°C while the outside temperature was -5°C. It is found that there is less flow occurred to the environment from conditioned volume at 2.5 3, 4 and 5 meter height cases. In these cases, the air curtain also contributes the heating of the conditioned room. But some ratio of the air flows through the atmosphere and the room cannot kept at the +7°C initial temperature at 6 m case. It is also found that the heating ratio at different blowing heights differs between 0,89-1,98 comparing the case without an air curtain